Partner Fund Management
Latest statistics and disclosures from PFM Health Sciences's latest quarterly 13F-HR filing:
- Top 5 stock holdings are HUM, HZNP, LLY, PEN, UNH, and represent 24.05% of PFM Health Sciences's stock portfolio.
- Added to shares of these 10 stocks: HUM (+$43M), BDX (+$37M), DXCM (+$34M), LEGN (+$23M), ACHC (+$23M), ASND (+$22M), ICUI (+$20M), ISRG (+$17M), HCA (+$15M), UHS (+$14M).
- Started 9 new stock positions in MRTX, BDX, IMVT, ICUI, LEGN, OM, ACHC, ASND, INBX.
- Reduced shares in these 10 stocks: JNJ (-$104M), MRK (-$83M), PEN (-$66M), , AXSM (-$49M), CI (-$47M), , AZN (-$39M), BMRN (-$38M), .
- Sold out of its positions in A, AZN, BIIB, BPMC, CI, CRL, ITOS, JNJ, JNCE, LH. OSH, LUNG, BHVN, JAZZ.
- PFM Health Sciences was a net seller of stock by $-424M.
- PFM Health Sciences has $2.3B in assets under management (AUM), dropping by -18.93%.
- Central Index Key (CIK): 0001442756
Tip: Access up to 7 years of quarterly data
Positions held by Partner Fund Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for PFM Health Sciences
PFM Health Sciences holds 74 positions in its portfolio as reported in the March 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Humana (HUM) | 5.4 | $123M | +52% | 254k | 485.46 |
|
| Horizon Therapeutics Pub L SHS (HZNP) | 5.3 | $119M | 1.1M | 109.14 |
|
|
| Eli Lilly & Co. Call Option (LLY) | 5.1 | $116M | +13% | 338k | 343.42 |
|
| Penumbra (PEN) | 4.4 | $100M | -39% | 360k | 278.69 |
|
| UnitedHealth (UNH) | 3.8 | $85M | -2% | 181k | 472.59 |
|
| Cytokinetics Com New (CYTK) | 3.7 | $84M | 2.4M | 35.19 |
|
|
| Centene Corporation (CNC) | 3.1 | $70M | 1.1M | 63.21 |
|
|
| Irhythm Technologies (IRTC) | 2.7 | $60M | 486k | 124.03 |
|
|
| Oak Str Health Note 3/1 (Principal) | 2.6 | $58M | -7% | 59M | 0.99 |
|
| Edwards Lifesciences (EW) | 2.4 | $54M | +22% | 649k | 82.73 |
|
| Dex (DXCM) | 2.2 | $49M | +212% | 424k | 116.18 |
|
| Merck & Co (MRK) | 2.2 | $49M | -62% | 461k | 106.39 |
|
| Cardinal Health (CAH) | 2.1 | $48M | 640k | 75.50 |
|
|
| Abbvie (ABBV) | 2.0 | $46M | -32% | 289k | 159.37 |
|
| Intuitive Surgical Com New (ISRG) | 2.0 | $46M | +56% | 179k | 255.47 |
|
| Seagen (SGEN) | 2.0 | $45M | +14% | 221k | 202.47 |
|
| Danaher Corporation (DHR) | 2.0 | $44M | 176k | 252.04 |
|
|
| Uniqure Nv SHS (QURE) | 1.9 | $43M | -8% | 2.1M | 20.14 |
|
| Syndax Pharmaceuticals (SNDX) | 1.8 | $41M | +7% | 1.9M | 21.12 |
|
| Iqvia Holdings (IQV) | 1.8 | $40M | -12% | 201k | 198.89 |
|
| Hca Holdings (HCA) | 1.7 | $39M | +61% | 149k | 263.68 |
|
| Argenx Se Sponsored Adr (ARGX) | 1.7 | $39M | 105k | 372.58 |
|
|
| Molina Healthcare (MOH) | 1.7 | $39M | 144k | 267.49 |
|
|
| McKesson Corporation (MCK) | 1.7 | $38M | 106k | 356.05 |
|
|
| Prothena Corp SHS (PRTA) | 1.7 | $38M | -24% | 775k | 48.47 |
|
| Axsome Therapeutics (AXSM) | 1.7 | $37M | -56% | 606k | 61.68 |
|
| Becton, Dickinson and (BDX) | 1.7 | $37M | NEW | 151k | 247.54 |
|
| Dynavax Technologies Corp Com New (DVAX) | 1.6 | $37M | 3.8M | 9.81 |
|
|
| Thermo Fisher Scientific (TMO) | 1.6 | $36M | 62k | 576.37 |
|
|
| Iveric Bio (ISEE) | 1.6 | $36M | +59% | 1.5M | 24.33 |
|
| Universal Hlth Svcs CL B (UHS) | 1.3 | $30M | +87% | 234k | 127.10 |
|
| Waters Corporation (WAT) | 1.3 | $29M | 95k | 309.63 |
|
|
| Avantor (AVTR) | 1.3 | $29M | -15% | 1.4M | 21.14 |
|
| Arcus Biosciences Incorporated (RCUS) | 1.3 | $29M | -42% | 1.6M | 18.24 |
|
| Tenet Healthcare Corp Com New Call Option (THC) | 1.2 | $28M | -2% | 468k | 59.42 |
|
| Caribou Biosciences (CRBU) | 1.2 | $27M | +12% | 5.0M | 5.31 |
|
| Karuna Therapeutics Ord (KRTX) | 1.1 | $25M | +6% | 138k | 181.64 |
|
| Point Biopharma Global (PNT) | 1.0 | $23M | -30% | 3.2M | 7.27 |
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 1.0 | $23M | NEW | 472k | 48.22 |
|
| Acadia Healthcare (ACHC) | 1.0 | $23M | NEW | 311k | 72.25 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 1.0 | $22M | NEW | 202k | 107.22 |
|
| ICU Medical, Incorporated (ICUI) | 0.9 | $20M | NEW | 123k | 164.96 |
|
| Apellis Pharmaceuticals (APLS) | 0.8 | $19M | -10% | 284k | 65.96 |
|
| BioCryst Pharmaceuticals (BCRX) | 0.8 | $18M | 2.2M | 8.34 |
|
|
| Nevro Corp Note 2.750% 4/0 (Principal) | 0.7 | $17M | 18M | 0.94 |
|
|
| Arcellx Common Stock (ACLX) | 0.7 | $16M | -14% | 526k | 30.81 |
|
| BioMarin Pharmaceutical (BMRN) | 0.7 | $16M | -71% | 160k | 97.24 |
|
| Biomarin Pharmaceutical Note 0.599% 8/0 (Principal) | 0.7 | $15M | -58% | 15M | 1.03 |
|
| Anthem (ELV) | 0.7 | $15M | -51% | 33k | 459.81 |
|
| Bluebird Bio (BLUE) | 0.6 | $15M | +1772% | 4.6M | 3.18 |
|
| Erasca (ERAS) | 0.6 | $14M | 4.8M | 3.01 |
|
|
| Icon SHS (ICLR) | 0.6 | $14M | -21% | 64k | 213.59 |
|
| Essa Pharma Com New (EPIX) | 0.5 | $12M | +8% | 4.2M | 2.97 |
|
| Mirati Therapeutics (MRTX) | 0.5 | $12M | NEW | 319k | 37.18 |
|
| Generation Bio (GBIO) | 0.5 | $11M | -8% | 2.6M | 4.30 |
|
| Procept Biorobotics Corp (PRCT) | 0.4 | $9.1M | -38% | 320k | 28.40 |
|
| Editas Medicine (EDIT) | 0.3 | $7.5M | -29% | 1.0M | 7.25 |
|
| Immunovant (IMVT) | 0.3 | $7.2M | NEW | 462k | 15.51 |
|
| Adaptimmune Therapeutics Sponds Adr (ADAP) | 0.3 | $6.5M | +23% | 6.0M | 1.09 |
|
| Outset Med (OM) | 0.3 | $6.0M | NEW | 325k | 18.40 |
|
| Werewolf Therapeutics (HOWL) | 0.3 | $5.8M | +71% | 2.2M | 2.60 |
|
| Xenon Pharmaceuticals (XENE) | 0.2 | $3.6M | +472% | 100k | 35.79 |
|
| Celcuity (CELC) | 0.1 | $3.2M | -56% | 311k | 10.25 |
|
| Bellus Health Com New (BLU) | 0.1 | $3.2M | +588% | 440k | 7.20 |
|
| Verve Therapeutics (VERV) | 0.1 | $2.7M | -14% | 186k | 14.42 |
|
| Compass Pathways Sponsored Ads (CMPS) | 0.1 | $2.4M | -51% | 246k | 9.93 |
|
| Inhibrx (INBX) | 0.1 | $2.3M | NEW | 121k | 18.87 |
|
| Pmv Pharmaceuticals (PMVP) | 0.1 | $2.0M | +25% | 418k | 4.77 |
|
| Praxis Precision Medicines I (PRAX) | 0.1 | $1.8M | -21% | 2.2M | 0.81 |
|
| Vectivbio Hldg Ord Shs (VECT) | 0.0 | $1.1M | +416% | 132k | 8.51 |
|
| Io Biotech (IOBT) | 0.0 | $952k | 508k | 1.88 |
|
|
| Keros Therapeutics (KROS) | 0.0 | $869k | +27% | 20k | 42.70 |
|
| Iovance Biotherapeutics (IOVA) | 0.0 | $868k | +965% | 142k | 6.11 |
|
| Sana Biotechnology (SANA) | 0.0 | $46k | -77% | 14k | 3.27 |
|
Past Filings by PFM Health Sciences
SEC 13F filings are viewable for PFM Health Sciences going back to 2010
- PFM Health Sciences 2023 Q1 filed May 15, 2023
- PFM Health Sciences 2022 Q4 filed Feb. 14, 2023
- PFM Health Sciences 2022 Q3 filed Nov. 14, 2022
- PFM Health Sciences 2022 Q2 filed Aug. 15, 2022
- PFM Health Sciences 2022 Q1 filed May 16, 2022
- PFM Health Sciences 2021 Q4 filed Feb. 14, 2022
- PFM Health Sciences 2021 Q3 filed Nov. 15, 2021
- PFM Health Sciences 2021 Q2 filed Aug. 16, 2021
- PFM Health Sciences 2021 Q1 filed May 17, 2021
- PFM Health Sciences 2020 Q4 restated filed Feb. 19, 2021
- PFM Health Sciences 2020 Q4 filed Feb. 16, 2021
- PFM Health Sciences 2020 Q3 filed Nov. 16, 2020
- Partner Fund Management 2020 Q2 filed Aug. 14, 2020
- Partner Fund Management 2020 Q1 filed May 15, 2020
- Partner Fund Management 2019 Q4 filed Feb. 14, 2020
- Partner Fund Management 2019 Q3 filed Nov. 14, 2019